SuperworthMetagenomi Therapeutics shares outstanding MGX
Diluted shares outstanding, averaged over each quarter, from 2023.
- Latest quarter, to Jun 30, 2026
- 37.7M
- On a year earlier
- +1.3%
- more shares
Metagenomi Therapeutics had 37.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 1.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 37.5M | +1% |
| FY2024 | 37.3M | +995% |
| FY2023 | 3.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 37.7M | +1% | |
| Q1 FY26 | 37.6M | +2% | |
| Q4 FY25 | 37.5M | +1% | |
| Q3 FY25 | 37.3M | +2% | |
| Q2 FY25 | 37.2M | +1% | |
| Q1 FY25 | 37M | +75% | |
| Q4 FY24 | 37.3M | +995% | |
| Q3 FY24 | 36.8M | +980% | |
| Q2 FY24 | 36.6M | +976% | |
| Q1 FY24 | 21.1M | +521% | |
| Q4 FY23 | 3.4M | n/a | |
| Q3 FY23 | 3.4M | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Metagenomi Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.